Abstract: . . .  reaching the final dose of 400 mg daily, as recommended, in two weeks (4). By the second month of his treatment, while renal functions were improving, the patient presented with progressive drowsiness without other symptoms. Laboratory studies showed: hemoglobin 7.7 g/dl, platelet count 42,000/mL, and D-dimer 1500 ng/ml (N:<500 ng/ml). Leukocyte count, prothrombin time, activated partial thromboplastin time and fibrinogen levels were normal. Arterial blood gas analysis showed hypoxemia with a PaO 2 of 58.5 mmHg, hypocapnia with a PaCO 2 of 38 mmHg and oxygen saturation of 92%. The chest radiograph was normal and the electrocardiogram showed sinus tachycardia. There were no evident neuropathological findings except confusion. On the cranial MR, a chronic infarction of the right posterior parietal lobe suggestive of arterial thrombosis was evident (Figure 1). Except for lytic lesions of the cranial bones, the computed tomography of the cranium before treatment with thalidomide was normal. We thus searched for evidence of an underlying thrombophilic state in the patient. DNA was extracted from blood and bone marrow and analyzed for the presence of genetic mutations related with cardiovascular risks. Factor V G1691A (Leiden), factor II G20210A (prothrombin), factor V H1299R(R2), MTHFR C 677T, B-fibrinogen-455 G-A, factor . . .
. . .  failure may be associated with unexplained hyperkalaemia. Br J Haemotol 2003; 122: 160-161. 6. Scarpace SL, Hahn T, Roy H, Brown K, Paplham P, Chanan-Khan A et al. Arterial thrombosis in four patients treated with thalidomide. Leuk Lymphoma 2005; 46: 239-242. 7. Bennet C, Schumock G, Desai A, Kwaan H, Raisch D, Newlin R. Thalidomide-associated deep vein thrombosis and pulmonary embolism. Am J Med 2002; 113: 603-606. 8. Bowcock SJ, Rassam SMV, Ward SM, Turner JT, Laffan M. Thromboembolism in patients on thalidomide for myeloma. Hematology 2002; 7: 51-53. 9. Zangari M, Anaissie E, Barlogie B, Badros A, Desikan R, Gopal AV et al. Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. Blood 2001; 98: 1614-1615.  . . .
--3000,2,750,2534,15854